Mannkind's current "cash burn" rate is about $40,000,000 a quarter. The company currently has about $100,000,000 in cash on hand.
Under a worse case scenaio I would think the company would need another another $150 million to operate through Afrezza's approval. Mannkind's CEO, Mr. Al Mann could fund this himself if he chose to do so.
I'm expecting at this point in time that Mannkind will partner or that Mr. Mann will sell the company.
Mr. Mann expected approval and had planned on having a stronger position when bargaining for the terms of a partnership.
Sanofi-Aventis would be my partner of choice. Glaxo would be my second choice.
Sanofi has billions of dollars in cash on hand and could assist with getting Afrezza approved in both the U.S. and Europe. It has spent more than $17 billion on 25 acquisitions over the last two years.
A partnership that would garner Mannkind an up front cash payment in the $200 million range with milestone payments to follow would be reasonable.
In addition to Afrezza Mannkind does have another ten drugs in various stages of development. One of them is a cancer vaccine that shows great promise.
Now is the time for Mannkind's Board of Director to push Mr. Mann to finalize an agreement with one of the "our partners" to which Mr. Mann keeps referring.
"Is there A Big Pharma "White Knight" In Mannkind's Future?"
WCoastGuynCA's Blog
27 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.